PM:NYSEPhilip Morris International Inc Analysis
Data as of 2026-03-09 - not real-time
$171.35
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Philip Morris International (PM) is trading at $171.35, well above its DCF‑derived fair value of $77.89, indicating the stock is currently overvalued. The price sits comfortably above the 20‑day SMA of 182.53 and the 50‑day SMA of 174.61, but below the 200‑day SMA of 167.48, suggesting a mixed medium‑term trend despite the model flagging a bullish direction. Technical momentum is mixed: the MACD is bearish (line –0.62 vs signal 1.94) while the RSI at 38 hints at near‑oversold conditions, and volume is increasing, supporting a potential short‑term bounce. Fundamentally, the company delivers strong profitability with a gross margin of 67% and operating margin of 33%, and revenue is growing 6.8% YoY, driven by robust smoke‑free product sales. The dividend yield of 3.46% and a payout ratio of 77.6% are supported by solid free cash flow of $8.94 bn, though the balance sheet shows high debt levels and a negative book value per share. Recent analyst upgrades and a live investor webcast underscore confidence in the company’s strategic shift toward reduced‑risk products, but regulatory scrutiny remains a headwind. Overall, the stock offers an attractive dividend and cash generation but appears priced for perfection, with upside limited by valuation and regulatory risk.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish trend direction with increasing volume
- MACD bearish divergence and near‑oversold RSI
- Current price above short‑term support but below resistance
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong margins and 6.8% revenue growth driven by smoke‑free products
- Sustainable dividend yield of 3.46% with solid free cash flow
- Analyst upgrades and positive investor sentiment (Extreme Greed index)
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Transition to reduced‑risk nicotine products providing growth runway
- Robust cash generation supporting dividend continuity
- Brand moat and global footprint offsetting regulatory pressures
Key Metrics & Analysis
Financial Health
Revenue Growth6.80%
Profit Margin27.92%
P/E Ratio23.6
ROA15.96%
P/B Ratio-26.7
Op. Cash Flow$12.2B
Free Cash Flow$8.9B
Technical Analysis
TrendBullish
RSI38.0
Support$166.90
Resistance$191.30
MA 20$182.53
MA 50$174.61
MA 200$167.48
MACDBearish
VolumeIncreasing
Fear & Greed Index100
Valuation
Fair Value$77.89
Target Price$194.84
Upside/Downside13.71%
GradeOvervalued
TypeBlend
Dividend Yield3.46%
Risk Assessment
Beta0.11
Volatility25.81%
Sector RiskLow
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.